Modalert: Enhance Wakefulness and Cognitive Performance
| Product dosage: 100mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 30 | $1.67 | $50.20 (0%) | 🛒 Add to cart |
| 60 | $1.22 | $100.40 $73.29 (27%) | 🛒 Add to cart |
| 90 | $1.07 | $150.60 $96.39 (36%) | 🛒 Add to cart |
| 120 | $0.99 | $200.80 $118.47 (41%) | 🛒 Add to cart |
| 180 | $0.91 | $301.20 $164.66 (45%) | 🛒 Add to cart |
| 270 | $0.87 | $451.81 $233.94 (48%) | 🛒 Add to cart |
| 360 | $0.84
Best per pill | $602.41 $302.21 (50%) | 🛒 Add to cart |
| Product dosage: 200mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 30 | $1.57 | $47.19 (0%) | 🛒 Add to cart |
| 60 | $1.14 | $94.38 $68.27 (28%) | 🛒 Add to cart |
| 90 | $0.99 | $141.57 $89.36 (37%) | 🛒 Add to cart |
| 120 | $0.92 | $188.75 $110.44 (41%) | 🛒 Add to cart |
| 180 | $0.85 | $283.13 $153.61 (46%) | 🛒 Add to cart |
| 270 | $0.81 | $424.70 $217.87 (49%) | 🛒 Add to cart |
| 360 | $0.78
Best per pill | $566.26 $281.12 (50%) | 🛒 Add to cart |
Modalert is a prescription medication containing modafinil, a wakefulness-promoting agent indicated for the improvement of wakefulness in patients with excessive sleepiness associated with narcolepsy, obstructive sleep apnea (OSA), and shift work sleep disorder (SWSD). It is classified as a Schedule IV controlled substance in the United States due to its potential for dependence. This product card provides a comprehensive, expert-level overview of Modalert, detailing its pharmacological profile, appropriate usage, and essential safety information for healthcare professionals and informed patients. It is not a substitute for professional medical advice, diagnosis, or treatment.
Features
- Active Ingredient: Modafinil (200 mg per tablet, standard dose).
- Pharmacologic Class: Wakefulness-promoting agent; not a typical stimulant.
- Mechanism of Action: Exact mechanism is unknown. It is believed to work by increasing dopamine in the brain by inhibiting dopamine reuptake. Its wake-promoting effects are also thought to be mediated through activation of hypothalamic wakefulness centers (e.g., tuberomammillary nucleus, orexin neurons), with minimal impact on other neurotransmitter systems compared to amphetamines.
- Dosage Form: Oral tablet.
- Time to Peak Plasma Concentration (Tmax): Approximately 2-4 hours.
- Elimination Half-life: 12-15 hours.
- Bioavailability: Not fully established, but well-absorbed.
- Metabolism: Primarily hepatic, via CYP3A4/5-mediated hydrolysis, with contributions from other enzymes (e.g., CYP2C9, CYP2C19). It is also an inducer of CYP3A4, CYP2C9, and CYP2C19.
- Excretion: Primarily renal (as metabolites; <10% as unchanged drug).
Benefits
- Promotes Sustained Wakefulness: Effectively reduces excessive daytime sleepiness, allowing for extended periods of alertness without the pronounced euphoria or severe “crash” associated with traditional stimulants.
- Improves Cognitive Function: Many users report enhancements in executive functions, including improved focus, concentration, working memory, and mental processing speed, particularly in states of sleep deprivation.
- Supports Occupational and Social Functioning: By mitigating the debilitating effects of sleep disorders, it enables individuals to maintain normal work schedules, operate machinery safely (where approved), and engage more fully in daily activities.
- Favorable Pharmacokinetic Profile: Its long half-life allows for once-daily dosing in most cases, promoting regimen adherence and providing consistent coverage throughout the waking day.
- Lower Abuse Potential: Compared to Schedule II stimulants like amphetamines, modafinil has a comparatively lower risk of abuse and dependence, though the risk is not absent.
Common use
Modalert (modafinil) is FDA-approved for the treatment of excessive sleepiness associated with:
- Narcolepsy: A chronic neurological disorder characterized by the brain’s inability to regulate sleep-wake cycles normally.
- Obstructive Sleep Apnea (OSA): As adjunctive therapy to standard treatments for OSA (e.g., continuous positive airway pressure, CPAP). It is used to treat residual sleepiness in adequately treated patients where the airway obstruction is effectively managed.
- Shift Work Sleep Disorder (SWSD): For individuals who experience insomnia during scheduled sleep times or excessive sleepiness during scheduled wake times due to a work schedule that overlaps with the typical sleep period.
It is also used off-label for a variety of conditions, including attention deficit hyperactivity disorder (ADHD), fatigue associated with multiple sclerosis, and depression. However, these uses are not approved by the FDA, and the evidence supporting efficacy varies.
Dosage and direction
- Standard Dosage: The recommended dose for most patients is 200 mg taken orally once daily.
- Administration: Administer in the morning for narcolepsy and OSA. For SWSD, administer approximately one hour prior to the start of the work shift.
- Dosage Adjustment: In elderly patients or those with severe hepatic impairment, a reduced dosage of 100 mg daily is recommended due to reduced clearance. No specific dosage adjustment is recommended for renal impairment, but caution is advised.
- Timing: Can be taken with or without food; however, a high-fat meal may delay absorption but does not significantly affect overall bioavailability.
- Duration: Use should be at the lowest effective dose and for the duration prescribed by a healthcare provider. Long-term use should be periodically re-evaluated.
Precautions
- Cardiovascular Effects: May increase heart rate and blood pressure. Blood pressure should be monitored regularly, especially in patients with underlying hypertension or cardiovascular disease.
- Psychiatric Symptoms: Has been associated with psychiatric adverse reactions such as anxiety, nervousness, insomnia, aggression, agitation, and depression. Use with caution in patients with a history of psychosis, mania, or depression.
- Dependence Potential: Although risk is lower than with amphetamines, Modalert is a Schedule IV controlled substance and has the potential for misuse, abuse, and dependence. A history of drug or alcohol addiction is a risk factor.
- Driving and Operating Machinery: Patients should be cautioned about operating automobiles or hazardous machinery until they are reasonably certain that Modalert does not adversely affect their performance (e.g., causing dizziness or other impairments).
- Pregnancy and Lactation: Modafinil is Pregnancy Category C. There are no adequate and well-controlled studies in pregnant women. It should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. It is excreted in breast milk; a decision should be made to discontinue nursing or discontinue the drug.
Contraindications
Modalert is contraindicated in patients with:
- Hypersensitivity to modafinil, armodafinil, or any inactive ingredient of the formulation.
- A history of left ventricular hypertrophy or ischemic ECG changes, chest pain, arrhythmia, or other clinically significant manifestations of mitral valve prolapse in association with CNS stimulant use.
Possible side effect
Common side effects (≥1%) include:
- Headache
- Nausea
- Nervousness
- Anxiety
- Insomnia
- Dizziness
- Diarrhea
- Dry mouth
- Rhinitis
Serious but less common side effects require immediate medical attention:
- Serious skin reactions (e.g., Stevens-Johnson Syndrome, toxic epidermal necrolysis, Drug Reaction with Eosinophilia and Systemic Symptoms [DRESS])
- Angioedema and anaphylactoid reactions
- Persistent psychiatric symptoms (hallucinations, suicidal ideation, mania)
- Symptoms of a heart problem (chest pain, irregular heartbeat, trouble breathing)
Drug interaction
Modalert has several clinically significant drug interactions:
- CYP3A4 Inducers/Inhibitors: As Modalert is metabolized by CYP3A4, strong inducers (e.g., carbamazepine, phenobarbital, rifampin) may decrease its efficacy, while strong inhibitors (e.g., ketoconazole, itraconazole) may increase modafinil plasma levels and the risk of adverse effects.
- CYP3A4/2C19 Substrates: Modalert induces CYP3A4 and may reduce the effectiveness of drugs metabolized by this enzyme (e.g., cyclosporine, ethinyl estradiol, midazolam, triazolam, certain statins). It may also induce CYP2C19, potentially reducing the efficacy of drugs like omeprazole, diazepam, and phenytoin.
- Warfarin (CYP2C9 substrate): Modalert may increase the metabolism of warfarin, potentially decreasing its anticoagulant effect. Prothrombin time/INR should be monitored closely during and after modafinil therapy.
- Other CNS Active Drugs: The concomitant use of Modalert with other psychoactive drugs (e.g., other stimulants, antidepressants, antipsychotics) may have additive effects or alter the effectiveness of either medication.
Missed dose
If a dose is missed, it should be taken as soon as possible on the same day. However, if it is late in the afternoon or evening, the missed dose should be skipped to prevent insomnia. Do not double the next dose to make up for a missed one.
Overdose
- Symptoms: Overdose may exaggerate the known pharmacological effects of modafinil, including insomnia, central nervous system excitation (e.g., restlessness, agitation, anxiety, confusion, tremor), tachycardia, hypertension, and gastrointestinal symptoms (e.g., nausea, diarrhea).
- Management: There is no specific antidote for modafinil overdose. Management involves symptomatic and supportive care, which may include cardiovascular monitoring and benzodiazepines for agitation. Gastric lavage may be considered if performed soon after ingestion. The value of dialysis is unknown.
Storage
- Store at room temperature, 20°C to 25°C (68°F to 77°F), with excursions permitted between 15°C and 30°C (59°F and 86°F).
- Keep in a tightly closed container, protected from light and moisture.
- Keep out of reach of children and pets.
Disclaimer
This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition or before starting any new treatment. Never disregard professional medical advice or delay in seeking it because of something you have read here. The unauthorized use, distribution, or possession of prescription medications is illegal.
Reviews
- Clinical Efficacy (5/5): “As a sleep specialist, I find modafinil to be a cornerstone of treatment for residual sleepiness in compliant CPAP users. Its efficacy is well-documented in robust clinical trials, and its side effect profile is generally more favorable than traditional stimulants.” – Dr. Eleanor Vance, MD, Sleep Medicine.
- Patient Experience (4/5): “After years of struggling with shift work disorder, Modalert gave me my life back. I am alert during my night shifts and can actually sleep during the day. The only downside is an occasional headache, which is manageable with hydration.” – J. Smith, Nurse.
- Cognitive Utility (4/5): “Prescribed off-label for ADHD after poor response to first-line treatments. The focus and mental clarity are remarkable without the jitteriness of methylphenidate. Requires careful monitoring for any mood changes.” – Dr. Ben Carter, Psychiatrist.
- Safety Profile (4/5): “A valuable tool in our arsenal. The need for vigilance regarding potential dermatologic and psychiatric reactions cannot be overstated. Patient education on these rare but serious risks is paramount.” – Clinical Pharmacist Review.